Trial Profile
A Phase II Clinical Trial of PRX-00023 Therapy in Localization-Related Epilepsy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Oct 2023
Price :
$35
*
At a glance
- Drugs Naluzotan (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- 06 Oct 2017 Status changed from recruiting to discontinued.
- 02 Sep 2017 Planned End Date changed from 30 Aug 2017 to 14 Mar 2018.
- 02 Sep 2017 Planned primary completion date changed from 30 Aug 2017 to 14 Mar 2018.